UNSPSC 51383900: Nonsteroidal anti inflammatory nicotinic acids

Nonsteroidal anti inflammatory drugs made from 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position.

UNSPSC 51383900 Nonsteroidal anti-inflammatory nicotinic acids is a Class code that encompasses the procurement of pharmaceutical products and health-related medications, though recent state and local solicitations show a wider scope than the code's nominal name suggests—including naloxone, over-the-counter products, and direct-to-manufacturer pharmacy programs. State and local issuing bodies pursuing this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances representing multiple states and municipalities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work ranges from direct procurement of specific pharmaceutical units to wholesaler-based distribution networks and exploratory market intelligence for alternative pharmacy benefit structures.

Recent activity spans Florida, Texas, and Minnesota-based cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory procurement tool preceding formal RFP issuance. MMCAP, administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 (responses due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with awards effective July 1, 2026 and a two-year contract term. All three opportunities impose standard compliance requirements including drug-free workplace certification, E-Verify, FDA compliance, and specific insurance coverages.